- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00001542
Fluconazole Prophylaxis of Thrush in AIDS
연구 개요
상세 설명
Oropharyngeal candidiasis (OPC) occurs in up to 93% of persons with human immunodeficiency virus (HIV) infection at some time during the course of their illness. OPC usually responds well to initial antifungal therapy, but with increasing immunodeficiency it usually recurs and can become resistant to clinical and microbiologic cure. Therapy usually begins with topical agents, followed by systemic therapy with azole antifungals when those fail. Amphotericin B is also used, but is less well tolerated and usually only effective in parenteral form. Because of its bioavailability and efficacy, fluconazole has become the most commonly used agent in treating OPC. Recurrences have often led to frequent re-treatment or prophylactic therapy with fluconazole. Daily prophylaxis with fluconazole (200 mg) has been shown to decrease the incidence of OPC. With the widespread and prolonged use of fluconazole reports of clinical failures and yeasts with decreased susceptibilities have appeared. This resistance appears to be associated with advanced immunosuppression and azole exposure. The most effective regimen to decrease relapse and morbidity from OPC which minimizes development of resistance has not been established. Could less frequent and/or lower dose prophylaxis with fluconazole decrease the incidence of recurrences while slowing the development of drug resistance?
We plan to perform a two phase study of low-dose fluconazole prophylaxis in HIV infected patients with a history of OPC. Patients with advanced immunosuppression (CD4 less than or equal to 150 cell/mm3) who have not received prior fluconazole prophylaxis will be included. Phase 1 of the study will be a placebo-controlled trial of fluconazole at a dose of 200 mg three times weekly. Phase 1 will examine whether this low-dose prophylaxis can delay recurrence of OPC. Phase 2 of the study will be an open-label prophylaxis with fluconazole at first 200mg thrice weekly, then 200mg daily as patients develop recurrent OPC. In this phase the primary question to be answered will be whether subjects starting in the placebo arm of Phase 1 will progress more or less rapidly to clinical fluconazole failure compared to those starting in the fluconazole arm. We will learn more about the natural history of fluconazole resistance, including how gradually the change occurs, how much fluconazole the patient has received at the time resistance develops and whether the resistance occurs in the patient's own isolate or from acquisition of a new isolate. Other evaluations will include compliance, cost, and host and organism-associated factors. If thrice weekly fluconazole prophylaxis can increase the time to development of resistance and decrease episodes of OPC in this group of severely immunocompromised individuals, it would increase the effective use (to include cost-effective use) of fluconazole in the treatment of OPC.
연구 유형
등록
단계
- 4단계
연락처 및 위치
연구 장소
-
-
Maryland
-
Bethesda, Maryland, 미국, 20892
- National Institute of Allergy and Infectious Diseases (NIAID)
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 어린이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
HIV infection previously documented by ELISA test kit and confirmed by either Western Blot, HIV antigen, HIV culture, or a second antibody test other than ELISA.
Age 18 years or older.
CD4 count of less than or equal to 150 cells/mm(3).
At least one prior episode of health care provider diagnosed oropharyngeal candidiasis in the 6 months preceding enrollment.
No allergy or intolerance to azoles.
Less than 3 episodes of oropharyngeal candidiasis within the last 3 months.
No history of esophageal candidiasis.
No presence of systemic fungal infection requiring continuous antifungal therapy.
No use of continuous azole treatment (i.e. daily, weekly, every other day, twice weekly fluconazole, itraconazole, ketoconazole or coltrimazole) for the prevention of fungal infections greater than or equal to 1 month within the past 6 months.
No severe liver disease (ALT or AST greater than 5 times the upper limit of normal).
No history of poorly responsive mucosal infection (i.e., requiring more than 200 mg of fluconazole daily or more than 14 days of therapy).
Females may not be pregnant or lactating. Must have a negative pregnancy test within 2 weeks of enrollment.
No one unlikely to survive more than 6 months.
Must have ability to tolerate oral medications.
No presence of active mucosal infection or symptoms of OPC/EC at time of initial assessment. (Note: Can enroll 2 weeks after resolution of the active episode).
No patients currently being treated with azole for recent mucosal infection. (Note: These patients can enroll 2 weeks after the completion of azole therapy.)
No presence of severe renal insufficiency as indicated by a serum creatinine greater than or equal to 3.0.
Women must be taking appropriate birth control measures.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
공동 작업자 및 조사자
간행물 및 유용한 링크
일반 간행물
- Powderly WG, Finkelstein D, Feinberg J, Frame P, He W, van der Horst C, Koletar SL, Eyster ME, Carey J, Waskin H, et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med. 1995 Mar 16;332(11):700-5. doi: 10.1056/NEJM199503163321102.
- Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother. 1995 Jan;39(1):1-8. doi: 10.1128/AAC.39.1.1. No abstract available.
- Grant SM, Clissold SP. Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs. 1990 Jun;39(6):877-916. doi: 10.2165/00003495-199039060-00006. Erratum In: Drugs 1990 Dec;40(6):862.
연구 기록 날짜
연구 주요 날짜
연구 시작
연구 완료
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
- RNA 바이러스 감염
- 바이러스 질환
- 감염
- 혈액 매개 감염
- 전염병
- 성병, 바이러스성
- 성병
- 렌티바이러스 감염
- 레트로바이러스과 감염
- 면역계 질환
- 악구강 질환
- 구강 질환
- 세균 감염 및 진균증
- 진균증
- 느린 바이러스 질환
- HIV 감염
- 칸디다 증
- 후천성면역결핍증후군
- 면역 결핍 증후군
- 칸디다증, 경구
- 약물의 생리적 효과
- 약리작용의 분자기전
- 항감염제
- 효소 억제제
- 호르몬, 호르몬 대체물 및 호르몬 길항제
- 시토크롬 P-450 효소 억제제
- 호르몬 길항제
- 항진균제
- 스테로이드 합성 억제제
- 14-알파 데메틸라제 억제제
- 시토크롬 P-450 CYP2C9 억제제
- 시토크롬 P-450 CYP2C19 억제제
- 플루코나졸
기타 연구 ID 번호
- 960108
- 96-I-0108
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
후천성면역결핍증후군에 대한 임상 시험
-
Icahn School of Medicine at Mount SinaiNational Institute on Deafness and Other Communication Disorders (NIDCD)완전한
-
Basaksehir Cam & Sakura Şehir Hospital완전한
-
China Medical University Hospital알려지지 않은
-
Wolfson Medical Center빼는Ovarian Hyperstimulation Syndrome(OHSS)의 위험 감소를 위한 Coasting에 대한 GnRH 길항제의 증량 투여
-
Jazz Pharmaceuticals모병결절성 경화증 복합 환자의 발작 | Dravet Syndrome 참가자의 발작 | 레녹스-가스토 증후군 참가자의 발작미국
-
Cure CMD모병Emery-Dreifuss 근이영양증 | 선천성 근무력증 증후군 | 림거들 근이영양증 | ITGA7(인테그린 알파-7) 결핍을 동반한 선천성 근이영양증 | 알파-디스트로글리칸병증(심각한 간질을 동반한 디스트로글리칸의 선천성 근이영양증 및 비정상적인 글리코실화) | 알파-디스트로글리칸병증(TRAPPC11 돌연변이로 인한 지방간 및 영아 발병 백내장을 동반한 선천성 근이영양증) | 알파-디스트로글리칸병증(디스트로글리칸의 저당화를 동반한 선천성 근이영양증) | 알파-디스트로글리칸병증(디스트로글리칸 및 간질의 저당화를 동반한 선천성 근이영양증) | 알파-디스트로글리칸병증(디스트로글리칸병증... 그리고 다른 조건미국
-
Sanford HealthNational Ataxia Foundation; Beyond Batten Disease Foundation; Pitt Hopkins Research Foundation 그리고 다른 협력자들모병미토콘드리아 질병 | 색소 성 망막염 | 중증 근무력증 | 호산구성 위장염 | 다계통 위축 | 평활근육종 | 백질이영양증 | 항문 누공 | 척수소뇌성 운동실조증 3형 | 프리드라이히 실조증 | 케네디병 | 라임 병 | 혈구탐식림프조직구증 | 척수소뇌성 운동실조증 1형 | 척수소뇌성 운동실조증 2형 | 척수소뇌성 실조증 6형 | 윌리엄스 증후군 | 히르슈스프룽병 | 글리코겐 축적병 | 가와사키병 | 짧은 창자 증후군 | 저인산증 | 레버 선천성 흑암시 | 입내 | 심장이완불능증 | 다발성 내분비선 종양 | 레이 증후군 | 애디슨병 | 제2형 다발성내분비선종양 | 경피증 | 제1형 다발성내분비선종양 | 다발성 내분비선 종양 유형 2A | 다발성 내분비선 종양 유형 2B | 비정형 용혈성... 그리고 다른 조건미국, 호주
플루코나졸에 대한 임상 시험
-
Daniel BenjaminPediatric Pharmacology Research Units Network완전한
-
Radboud University Medical Center아직 모집하지 않음관상동맥 질환 | 전신 염증 반응 증후군 | 체외순환; 합병증 | 수술 후 충격네덜란드
-
University of Pharmacy, Yangon완전한
-
University of MinnesotaNational Institute of General Medical Sciences (NIGMS)완전한
-
The Hospital for Sick ChildrenSt. Justine's Hospital; University of Waterloo완전한